Blood test could replace gadolinium scans for MS monitoring

NCT ID NCT07292480

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether monthly blood tests for a nerve damage marker (neurofilament light chain) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (MS) earlier than standard yearly MRI scans. The goal is to reduce the need for gadolinium-based contrast agents in MRI and allow faster treatment adjustments. The study will compare 84 participants on monthly blood monitoring against standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: monthly blood test for neurofilament light chain (pNfL)
What this could lead to: If successful, this could lead to a simpler, safer way to monitor MS and catch silent disease activity early, allowing faster treatment changes.
What could go wrong: This is a small, early-phase study. The blood test may not reliably detect all hidden activity, and results may not change long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING

Contacts and locations

Locations

CHU de Nice
RECRUITING

Nice, France
CHU de Nîmes
RECRUITING

Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.